Li Jiao, Shen Zhen, Wang Zheng, Chao Hongying, Xu Yi, Zeng Zhao, Bian Xiaosen, Zhang Jun, Pan Jinlan, Miao Weiwei, Wu Wenzhong, Yao Li, Chen Suning, Wen Lijun
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, P. R. China.
Hematology Department, Yixing People's Hospital of Jiangsu Province, Yixing, Wuxi, P. R. China.
J Leukoc Biol. 2022 May;111(5):981-987. doi: 10.1002/JLB.2A0720-441RR. Epub 2021 Oct 8.
ETO2 is a nuclear co-repressor, which plays a critical role in the regulation of the cell cycle, self-renewal capacity, and differentiation of hematopoietic progenitor cells. We identified novel fusion transcripts involving ETO2 and CTCF by RNA-seq in a multiple relapsed AML case. The CTCF-ETO2 and ETO2-CTCF chimeric genes were validated by RT-PCR and Sanger sequencing. In addition, both transcripts apparently promoted cell proliferation via JAK/STAT3 pathway that is sensitive to STAT3 inhibitors. The novel fusions may have prognostic value and pathogenic mechanisms in acute myeloid leukemia.
ETO2是一种核共抑制因子，在造血祖细胞的细胞周期调控、自我更新能力和分化过程中发挥关键作用。我们通过RNA测序在一例多次复发的急性髓系白血病（AML）病例中鉴定出了涉及ETO2和CTCF的新型融合转录本。CTCF-ETO2和ETO2-CTCF嵌合基因通过逆转录聚合酶链反应（RT-PCR）和桑格测序得到验证。此外，这两种转录本显然都通过对STAT3抑制剂敏感的JAK/STAT3途径促进细胞增殖。这些新型融合基因可能在急性髓系白血病中具有预后价值和致病机制。
